登录
| 企业文档数据库
  • 首页
  • 医学材料
    • 指南共识
    • 循证证据
    • 推荐观点
    • 临床项目
  • 产品信息/适应症
    • 宁泌泰胶囊
    • 夏枯草口服液
    • 苦参凝胶
    • 坤泰胶囊
    • 注射用西维来司他钠
    • 佐愈
    • 蒂诺安
    • 匹瑞
    • 卫达甘
  • 市场材料
    • 应用场景
    • 推荐观点
    • 市场活动
    • 绿卡
    • 事业部医学支持
    • 案例中心
  • 科室及医护人员
    • 内科
    • 外科
    • 重点科室
    • 医护群体
登录
  1. 首页
  2. 医学材料
  3. 循证证据
  4. 产品信息/适应症
  5. 汇伦医药
  6. 注射用西维来司他钠
  7. 科室及医护人员
  8. 内科
  9. 重点科室
  10. ICU
  11. 急诊
  12. 感染科
  13. 综合ICU
  14. 急诊ICU
  15. 呼吸ICU
  16. 正文

National incidence and mortality of hospitalized sepsis in China

收藏
文章来源:
摘要:Background: Sepsis is a leading cause of preventable death around the world. Population-based estimation of sepsis incidence is lacking in China. In this study, we aimed to estimate the population-based incidence and geographic variation of hospitalized sepsis in China. Methods: We retrospectively identified hospitalized sepsis from the nationwide National Data Center for Medical Service (NDCMS) and the National Mortality Surveillance System (NMSS) by ICD-10 codes for the period from 2017 to 2019. In-hospital sepsis case fatality and mortality rate were calculated to extrapolate the national incidence of hospitalized sepsis. The geographic distribution of hospitalized sepsis incidence was examined using Global Moran's Index. Results: We identified 9,455,279 patients with 10,682,625 implicit-coded sepsis admissions in NDCMS and 806,728 sepsis-related deaths in NMSS. We estimated that the annual standardized incidence of hospitalized sepsis was 328.25 (95% CI 315.41-341.09), 359.26 (95% CI 345.4-373.12) and 421.85 (95% CI 406.65-437.05) cases per 100,000 in 2017, 2018 and 2019, respectively. We observed 8.7% of the incidences occurred among neonates less than 1 year old, 11.7% among children aged 1-9 years, and 57.5% among elderly older than 65 years. Significant spatial autocorrelation for incidence of hospitalized sepsis was observed across China (Moran's Index 0.42, p = 0.001; 0.45, p = 0.001; 0.26, p = 0.011 for 2017, 2018, 2019, respectively). Higher number of hospital bed supply and higher disposable income per capita were significantly associated with a higher incidence of hospitalized sepsis. Conclusion: Our study showed a greater burden of sepsis hospitalizations than previous estimated. The geographical disparities suggested more efforts were needed in prevention of sepsis.
标签: 脓毒症 产品信息/适应症 汇伦医药 西维来司他钠 ICU 外科 内科 急诊
查看数:136
发布时间:2024-09-04 邹文成
公开


文档附件清单
  • 附件1: 脓毒症8-National incidence and mortality of hospitalized sepsis in China.pdf 下载附件
评论
0
      医学材料热门文章
      • 1. 急性呼吸窘迫综合征抗炎治疗中中性粒细胞弹性蛋白酶抑制剂急诊应用专家共识
      • 2. A New Global Definition of Acute Respiratory Distress Syndrome
      • 3. 中国创伤性脊髓损伤流行病学和疾病经济负担的系统评价
      • 4. 西维来司他钠联合俯卧位通气在急性肺损伤/急性呼吸窘迫综合征中的疗效评价
      • 5. 西维来司他钠治疗ARDS患者的效果及其应用价值
      • 6. The Protective Effects of Sivelestat Sodium on the Basis of Corticosteroid Therapy in Patients With Moderate-to-Severe Acute Respiratory Distress Syndrome
      • 7. 西维来司他钠对颅脑损伤合并ARDS患者的一项多中心、前瞻性、双盲、随机对照试验
      • 8. 西维来司他钠在ICU不同疾病合并ARDS患者中的应用效果
      • 9. 西维来司他钠在中国重症肺炎患者中的群体药代动力学
      • 10. 西维来司他钠与乌司他丁对急性Stanford A型主动脉夹层手术患者术后切口感染的效果对比
      热门文章
      • 1. 急性呼吸窘迫综合征抗炎治疗中中性粒细胞弹性蛋白酶抑制剂急诊应用专家共识
      • 2. A New Global Definition of Acute Respiratory Distress Syndrome
      • 3. 中国创伤性脊髓损伤流行病学和疾病经济负担的系统评价
      • 4. 西维来司他钠联合俯卧位通气在急性肺损伤/急性呼吸窘迫综合征中的疗效评价
      • 5. 西维来司他钠治疗ARDS患者的效果及其应用价值
      • 6. 希为纳EDA
      • 7. The Protective Effects of Sivelestat Sodium on the Basis of Corticosteroid Therapy in Patients With Moderate-to-Severe Acute Respiratory Distress Syndrome
      • 8. 希为纳围术期病例库(心外/神外/胸外/肝胆外)
      • 9. 西维来司他钠对颅脑损伤合并ARDS患者的一项多中心、前瞻性、双盲、随机对照试验
      • 10. 西维来司他钠在ICU不同疾病合并ARDS患者中的应用效果

      版权所有 © 上海汇伦医药股份有限公司 沪ICP备17025706号-2